Multiple squamous cell carcinomas following introduction of nilotinib. (1st October 2014)

• Record Type: Journal Article
• Authors: Peters, P.; Rabbolini, D.; Sinnya, S.; Khosrotehrani, K.; Wagner, G.
• Is Part Of: Clinical and experimental dermatology. Volume 39:Number 7(2014)
• Page Start: 791
• Page End: 794
• Publication Date: 2014-10-01
• Subjects: Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/ced.12388
• Languages: English
• ISSNs: 0307-6938

Abstract

Summary: Background: Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). Methods: We assessed a 72‐year‐old woman who was treated with nilotinib for CML. Results: During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs. Conclusions: Development of SCC is a previously unreported adverse reaction to nilotinib.